Bone Marrow-derived Mesenchymal Stem Cells (MSC) Administration in Weaning From Left Ventricular Assist Device
Status:
Withdrawn
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
Left Ventricular Assist Devices are commonly used to assist failing hearts as a bridge to
transplantation or for long-term support. The purpose of the MESenchymal stem cell therapy
and Left Ventricular Assist Device program is to improve heart function with stem cell
therapy and attempt to wean patients from HeartMate Left Ventricular Assist Device.